Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...

Buzz on the Bullboards: Looking for volatility-proof stocks?

This week, investors witnessed significant developments in Canadian and U.S. markets, with attention drawn to the pivotal decisions made by central banks and notable movements in key sectors. Let’s get into the highlights of the past week’s...

Buzz on the Bullboards: Who is shining through the market slump?

The market story this week has been less impressive on both sides of the border than what we saw in the week where February turned to March. Recent losses and flatline trading have negated Wall Street’s previous record-setting run where major U.S. indices ...

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...

Medicus Pharma advances cancer treatment towards phase II trial

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Our next company is Medicus Pharma Ltd. (TSXV:MDCX) , headquartered in Philadelphia, Pennsylvania. The company is a publicly traded clinical stage, multi-st...

Pharmaceutical company treats bladder cancer with new tech

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Theralase Technologies Inc. (TSXV:TLT) , a clinical-stage pharmaceutical company, is currently developing an innovative, research-backed technology for the ...

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...

Buzz on the Bullboards: Markets underperforming, or is the best yet to come?

So, the “September rally” didn’t really pan out as many indices hit lows not seen in months, but at least interest rates were kept firm for now, so that is some good news, right? Investors have been worried about the possibility o...

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...

Buzz on the Bullboards: Can health care and energy stocks help “recession proof” your portfolio?

Investors often keep focused on the most consistent plays, when times of renewed uncertainty rears its head in the markets. The recent wave of uncertainty follows the earlier wave, both caused by the U.S. debt ceiling deal and worries over an impending rec...
1 2 3 4 5 6 7 8 9 10 ...